C. B. Zartman

发表

Biochemical and structural characterization of a novel class of inhibitors of the type 1 insulin-like growth factor and insulin receptor kinases.

S. Stirdivant, L. Kuo, P. Darke, 2005, Biochemistry.

Identification of a novel RAMP-independent CGRP receptor antagonist.

J. Vacca, S. Graham, R. Z. Rutledge, 2011, Bioorganic & medicinal chemistry letters.

Oxo-piperazine derivatives of N-arylpiperazinones as inhibitors of farnesyltransferase.

J. Davide, N. Kohl, R. Lobell, 2001, Bioorganic & medicinal chemistry letters.

Acetonitrile/water gas-phase reaction products observed by use of atmospheric pressure chemical ionization: adducts formed with sulfonamides.

D. Wisnoski, C. W. Ross, H. Ramjit, 2005, Rapid communications in mass spectrometry : RCM.

[(11)C]MK-4232: The First Positron Emission Tomography Tracer for the Calcitonin Gene-Related Peptide Receptor.

Sandra M. Sanabria-Bohórquez, L. Gantert, E. Hostetler, 2013, ACS medicinal chemistry letters.

MK-8825: a potent and selective CGRP receptor antagonist with good oral activity in rats.

J. Vacca, H. Selnick, S. Graham, 2012, Bioorganic & medicinal chemistry letters.

Arylmethanesulfonates are convenient latent phenols in the nucleophilic aromatic substitution reaction

C. Dinsmore, C. B. Zartman, 1999 .

Potent benzimidazolone-based CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, Victor K. Johnston, 2008, Bioorganic & medicinal chemistry letters.

Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.

Cory R. Theberge, J. Vacca, J. Hochman, 2006, Bioorganic & medicinal chemistry letters.

Selective electrolytic fluorinations in 70% HF/30% pyridine

S. Harrison, W. Middleton, Corrie A. Stankiewicz, 1996 .

3-Aminopyrrolidinone farnesyltransferase inhibitors: design of macrocyclic compounds with improved pharmacokinetics and excellent cell potency.

A. D. Rodrigues, J Christopher Culberson, Ronald Robinson, 2002, Journal of medicinal chemistry.

N-arylpiperazinone inhibitors of farnesyltransferase: discovery and biological activity.

J. Huff, J. Davide, N. Kohl, 1999, Journal of medicinal chemistry.

Non-peptide calcitonin gene-related peptide receptor antagonists from a benzodiazepinone lead.

J. Vacca, P. Kunapuli, S. Graham, 2006, Bioorganic & medicinal chemistry letters.

Efficient synthesis of substituted piperazinones via tandem reductive amination–cyclization

C. Dinsmore, C. B. Zartman, 2000 .

Synthesis of conformationally constrained 5,6,7, 8-Tetrahydroimidazo[1,5-a]pyridine inhibitors of farnesyltransferase.

J. Huff, T. Olah, I. Chen, 2000, Organic letters.

Conformational restriction of flexible ligands guided by the transferred noe experiment: potent macrocyclic inhibitors of farnesyltransferase.

J. Huff, M. Bogusky, S. Graham, 2001, Journal of the American Chemical Society.

Substituted alkylpyridines as P3′ ligands for the hydroxyethylpiperazine class of HIV-1 protease inhibitors: Improved pharmacokinetic profiles

P. Anderson, P. Darke, W. Schleif, 1995 .

Identification of potent, highly constrained CGRP receptor antagonists.

Steven S. Sharik, Cory R. Theberge, J. Vacca, 2010, Bioorganic & medicinal chemistry letters.

Discovery of MK-3207: A Highly Potent, Orally Bioavailable CGRP Receptor Antagonist.

J. Vacca, C. Regan, T. Prueksaritanont, 2010, ACS medicinal chemistry letters.